ENTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs...

Stats
Šios dienos apimtis	118 877
Vidutinė apimtis	233 156
Rinkos kapitalizacija	70.25M
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $-0.0600 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.39
ATR14	$0.00800 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Yaacov-garbeli Dana	Buy	130 000	Stock Option (right to buy)
2024-04-19	Yaacov-garbeli Dana	Buy	30 151	Ordinary Shares, par value NIS 0.0000769 per share
2024-04-19	Galitzer Hillel	Buy	130 000	Stock Option (right to buy)
2024-04-19	Galitzer Hillel	Buy	30 151	Ordinary Shares, par value NIS 0.0000769 per share
2024-01-12	Taitel Haya	Buy	9 500	Ordinary Shares, par value NIS 0.0000769 per share

INSIDER POWER
100.00
Last 93 transactions
Buy: 4 653 836 \| Sell: 4 161 674

Tūris Koreliacija

Ilgas: -0.58 (weak negative)

Trumpas: 0.93 (very strong)

Signal:(56.608) Expect same movement, but be aware

Entera Bio Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TITN	0.854
TBLA	0.849
OPNT	0.84
OFIX	0.838
NAVI	0.835
LCAA	0.834
ATEC	0.831
ALSA	0.828
WDAY	0.827
GLLI	0.825

10 Labiausiai neigiamai susiję koreliacijos
AVO	-0.847
BLIN	-0.845
GETVV	-0.84
GLUE	-0.839
SIDU	-0.837
ATAI	-0.824
BIMI	-0.819
CEG	-0.816
DRUG	-0.814
GPOR	-0.813

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Entera Bio Ltd Koreliacija - Valiuta/Žaliavos

0.10
( neutral )

0.09
( neutral )

0.00
( neutral )

0.53
( weak )

-0.13
( neutral )

Entera Bio Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-56 000.00 (0.00 %)
EPS:	$-0.310

FY	2023
Pajamos:	$0
Bruto pelnas:	$-56 000.00 (0.00 %)
EPS:	$-0.310

FY	2022
Pajamos:	$134 000
Bruto pelnas:	$33 000.00 (24.63 %)
EPS:	$-0.450

FY	2021
Pajamos:	$571 000
Bruto pelnas:	$198 000 (34.68 %)
EPS:	$0.425

Financial Reports:

No articles found.

Entera Bio Ltd

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Realaus laiko atnaujinimai Entera Bio Ltd [ENTX]

Upcoming Earnings Alert